exai bio

We’re excited to welcome Michael Nall as CEO and Board Director and new Board Directors - Steve Kafka, PhD, of S32, Dusan Perovic of Two Sigma Ventures and Emir Sandhu, MD, of Blue Venture Fund. Their leadership will be invaluable as we advance our RNA & AI liquid biopsy platform.

Reflecting on a productive week of meetings at ASCO! Thank you to all those who visited our Innovation Hub booth to learn more about our technology. #ASCO25 #LiquidBiopsy #AI #RNA

Congratulations to our Board Director Karen Knudsen MBA PhD for receiving the 2025 Allen Lichter Visionary Leader Award from American Society of Clinical Oncology (ASCO). We are so grateful for your leadership, passion and the profound impact you have on the cancer community. #ASCO25 #Leadership

💥New Publication Alert in Clinical Cancer Research💥
We are thrilled to announce our latest publication on our novel RNA and generative AI liquid biopsy platform for early colorectal cancer detection. #EarlyDetection #LiquidBiopsy #RNA
Read the full publication here: aacrjournals.org/clincancerre...

Detection of early stage colorectal cancer using cell-free oncRNA biomarkers and AI We demonstrate high sensitivity and specificity were achieved, including 80% sensitivity for stage I CRC with a novel small RNA biomarker, oncRNA, combined with generative AI detects early-stage CRC u...

www.exai.bio/publications...

Amir Momen-Roknabadi representing Exai Bio at AACR 2025

Exai Bio presented new data demonstrating the power of its RNA and AI based liquid biopsy platform to detect colorectal cancer. Stage I sensitivity in an independent cohort was 80%, exceeding other blood based approaches. Thanks to Amir Momen-Roknabadi for representing Exai Bio at #AACR25!

DYK almost half of all women have dense breast tissue which means they are at higher risk of developing breast cancer? Exai is joining My Density Matters to spread awareness that today is Find Out My Breast Density Day. Talk to your doctor if you have questions. #BreastDensity #EarlyDetection

Together we unite to fight cancer and inspire hope.
#WorldCancerDay #UnitedByUnique #EarlyDetection #BreastCancer

Congratulations to our Board Director Karen Knudsen for receiving the 2025 Allen Lichter Visionary Leader Award from American Society of Clinical Oncology (ASCO). Your tremendous leadership and dedication continue to make a profound impact on cancer care. #ASCO25
connection.asco.org/do/asco-cong...

Behind the paper: Deep generative AI models analyzing circulating orphan non-coding RNAs enable detection of early-stage lung cancer Our recent study in Nature Communications highlights the success of a custom generative AI framework in detecting non-small cell lung cancer and its subtypes from serum-derived orphan non-coding RNAs.

Our own Mehran Karimzadeh wrote a blog post about our recent Nature Communications publication demonstrating superior cancer detection performance by Exai’s AI platform compared to traditional machine learning methods. #AI #EarlyDetection #LungCancer
communities.springernature.com/posts/behind...

Today, we honor the legacy of Dr. Martin Luther King Jr., whose words continue to inspire: “The time is always right to do what is right.” At Exai, we are committed to doing what is right—advancing cancer detection and ensuring a future where everyone has access to early detection and better health.

We are honored to welcome Karen E. Knudsen, MBA, PhD, to our board of directors. As an internationally recognized oncology leader and immediate past CEO of the American Cancer Society and its advocacy affiliate ACS CAN, Karen is deeply committed to ending cancer as we know it.

Deep generative AI models analyzing circulating orphan non-coding RNAs enable detection of early-stage lung cancer Nature Communications - A generative AI model, Orion, learns a robust and generalizable pattern of non-small cell lung cancer from cancer-specific circulating non-coding RNAs. Orion enhances the...

💥New Publication Alert in Nature Communications 💥
Our latest publication features our novel generative AI platform, showcasing superior performance in detecting lung cancer compared to traditional machine learning methods.
Read the full publication here: www.nature.com/articles/s41...

Exai was proud to be part of the inaugural RISE UP For Breast Cancer Meeting hosted by UCSF. #breastcancer #womenshealth #UCSF

3 years of innovation never looked so sweet! Celebrating Exai’s 3rd anniversary today, one donut (and breakthrough) at a time! #lifeatexai

Exai was proud to attend #ESMO2024, where we announced new data demonstrating the ability of our RNA liquid biopsy platform to determine breast cancer tumor ER and HER2 status. #liquidbiopsy #breastcancer

Join us at #ESMO2024 where Exai will present new data demonstrating the ability of our RNA liquid biopsy platform to determine breast cancer tumor ER and HER2 status. #liquidbiopsy #breastcancer

We’re excited to announce Dave Daly has been appointed as Exai Bio’s CEO. Dave brings more than 30 years of extensive cancer diagnostics and executive leadership experience to lead the next chapter of Exai.
www.exai.bio/news/exai-bi...

Exai celebrates diversity and wishes everyone a very happy Pride Month. #PrideMonth #earlydetection #lifeatexai #MRD

Proud to present our latest RNA- and AI-based #liquidbiopsy research at #ASCO24! #earlydetection #lifeatexai #MRD

Join Exai at #ASCO24 where we will share promising new data. #earlydetection #MRD

Exai co-founder, Hani Goodarzi, in collaboration with Dr. Laura Essserman and Dr. Laura van ‘t Veer from UCSF, posted a preprint, which provides the history of oncRNAs and their power to predict clinical outcomes and monitor disease burden based on the I-SPY 2 Trial. www.biorxiv.org/content/10.1...

The Exai team had a productive week at #AACR24! We were proud to showcase our #liquidbiopsy research in both early cancer detection and MRD.  #earlydetection #lifeatexai #MRD

Today, Exai presents new MRD data at #AACR24: Our onc-RNA- & AI-based #liquidbiopsy platform can accurately predict survival for patients with TNBC with residual disease, suggesting Exai can aid in tailoring adjuvant treatment for TNBC patients. #MRD #lifeatexai www.exai.bio/news/exai-bi...

At #AACR24, Exai’s novel oncRNA- & AI-based #liquidbiopsy platform breaks new barriers in early detection: Our platform detects breast cancer at the earliest stages with high accuracy and also distinguishes low grade DCIS from invasive breast cancer. #earlydetection  www.exai.bio/news/exai-bi...

What if a simple blood test could detect cancer? Catching cancer at its earliest stages saves lives. But in a body made up of trillions of cells, how do you spot a small group of rogue cancer cells? Biomedical researcher Hani Goodarzi discusses his ...

Exai is charting a new path to more effectively detect cancer at its earliest stages from a routine blood draw. In his TED Talk, Exai’s co-founder Hani Goodarzi describes how analyzing novel RNA biomarkers using advanced AI has the potential to redefine liquid biopsy. go.ted.com/hanigoodarzi